Abstract 5147
Background
Patient rights has been developed from human rights. Human rights emerged from the Universal Declaration of Human Rights. The Declaration is a milestone document in the history of human rights (1). Today the patient’s rights have become an important issue on the political agenda. Individual’s awareness of their own rights in the health area is constantly increasing. Patient’s rights are becoming primary concern in improving quality of health care (2). Today the patient becomes the consumer (3). The most important role that nurses have is delivering quality care for the patients and also act as patient advocates. Nurses must understand the importance of patient rights. The main aim of the survey is to analyze, investigate, compare and present, the legal framework of the patient’s rights legislation in the European Union.
Methods
A literature search and review related to the patient right was conducted using PubMed, Cinahl, Medline and Google Scholar. With descriptive method we set up a theoretical framework of the patient’s rights legislation. We also use comporative method to discover the similarities and differences between legal systems and their components.
Results
Patient’s rights are in thirteen European Member States regulated by specific law - Law on patient’s rights.
Conclusions
EU Member States do not have a common legislation for patient’s rights. Patient’s rights vary from country to country. Some countries have a single law or act, others use multiple pieces of legislation. Nurses are an important voice of the patient. References: 1. Universal Declaration of Human Rights. Avalible at: Https://www.un.org/en/universal-declaration-human-rights/ (10. 4. 2019). 2. Opinion of the European Economic and Social Committee on Patients’ rights. Official Journal EU, C10/67. Avalible at: Https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:010:0067:0071:EN:PDF (10. 4. 2019). 3. OECD - Patients, Patient Organisations and the Production of Medical Science and Technology. Avalible at: Http://www.oecd.org/education/innovation-education/32126031.pdf (10. 4. 2019). 4. Kozuh M., 2016. Legal Arrangements for the Protection of Patients’ Rights: A Comparative Overview of the Regulation in the EU (Master Thesis). University of Primorska Slovenia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maja Kozuh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract